证券代码：301103 证券简称：何氏眼科 公告编号：2023-033 辽宁何氏眼科医院集团股份有限公司 第三届董事会第一次会议决议公告 （一）审议通过《关于提请豁免公司第三届董事会第一次会议通知时限的 议案》 因该次董事会通知发出时间为 2023 年 8 月 10 日，鉴于公司现有董事已充 分知晓公司第三届董事会第一次会议议程及待审议议案内容，董事会对该次会议 的通知期限进行豁免。 表决结果：同意 7 票；反对 0 票；弃权 0 票； （二）审议通过《关于选举公司第三届董事会董事长的议案》 经全体董事审议，同意选举何伟先生为公司第三届董事会董事长，任期三年， 自公司本次董事会审议通过之日起至公司第三届董事会任期届满之日止。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日召开了 2023 年第一次临时股东大会，选举产生第三届董事会成员。经全 体董事一致提议并同意豁免临时董事会通知时限，第三届董事会第一次会议通知 于当日以口头等方式发出。第三届董事会第 ...

辽宁何氏眼科医院集团股份有限公司独立董事 关于第三届董事会第一次会议相关事项的 独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《公司章程》及《辽宁何氏眼科医院集团股份有 限公司独立董事工作制度》等有关规定，我们作为辽宁何氏眼科医院集团股份有限 公司（以下简称"公司"）的独立董事，经认真审阅公司第三届董事会第一次会议 相关文件，听取相关说明，基于独立、客观、公正的判断立场，发表如下独立意见： 1、本次公司聘任高级管理人员的提名和审议程序符合《公司法》《公司章程》 等有关法律、法规的规定，程序合法有效。 2、经对高级管理人员简历及相关资料的审查，我们认为其均具备担任相应职 务所需的管理能力、专业能力、职业道德，符合履行相关职责的要求，未发现有 《公司法》《公司章程》等有关法律、法规中不得担任公司高级管理人员的情形； 未发现存在被中国证监会采取证券市场禁入措施的情形；未被证券交易所公开认定 为不适合担任上市公司董事、监事和高级管理人员；未受过中国证监会行政处罚和 证券交易所公开谴责或者通报批评；未因涉嫌犯罪被司法机关立案侦查或者涉嫌违 法违规被中国证 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2023-032 辽宁何氏眼科医院集团股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次股东大会无增加、变更、否决提案的情况。 2.本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席情况 1. 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）2023 年第一 次临时股东大会于 2023 年 8 月 10 日召开，公司董事会已于 2023 年 7 月 14 日 在巨潮资讯网上刊登了《关于召开 2023 年第一次临时股东大会的通知公告》。 2.会议召开方式：本次股东大会采用现场和网络投票相结合的方式召开。 3.本次股东大会由公司董事会召集，现场会议由公司董事长何伟先生主持， 会议的召集、召开符合《公司法》、《上市公司股东大会规则》、《深圳证券交易所 创业板股票上市规则》及《公司章程》等规定。 4.会议召开日期和时间： 现场会议时间为：2023 年 8 月 10 日（星期四）14：00 网络投票时间为：2023 年 8 月 ...

证券代码：301103 证券简称：何氏眼科 公告编号：2023-035 辽宁何氏眼科医院集团股份有限公司 关于完成董事会、监事会提前换届选举 及聘任高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）于 2023 年 8 月 10 日召开 2023 年第一次临时股东大会，选举产生 4 名非独立董事和 3 名独立董 事，共同组成公司第三届董事会；选举产生 2 名非职工代表监事，与公司召开的 职工代表大会选举产生的 1 名职工代表监事共同组成公司第三届监事会。任期均 为自公司 2023 年第一次临时股东大会选举通过之日起三年。 2023 年 8 月 10 日，公司召开第三届董事会第一次会议、第三届监事会第一 次会议，选举产生董事长、董事会专门委员会委员及监事会主席，并聘任高级管 理人员及证券事务代表。现将相关内容公告如下： 一、第三届董事会组成情况 非独立董事：何伟先生（董事长）、何向东先生、周晋峰先生、李萍萍女士； 独立董事：王厚双先生、李慧女士（会计专业人士）、朱杰女士。 以上董 ...

辽宁何氏眼科医院集团股份有限公司董事会 战略委员会工作细则 第一章 总 则 第一条 为适应公司战略发展需要，增强公司核心竞争力，确定公司发展规 划，健全投资决策程序，加强决策科学性，提高重大投资决策的效益和决策的质 量，完善公司治理结构，根据《中华人民共和国公司法》、《上市公司治理准则》、 和《辽宁何氏眼科医院集团股份有限公司章程》（以下简称"《公司章程》"） 等规定，公司董事会特设立战略委员会，并制定本工作细则。 第二条 董事会战略委员会（以下简称"战略委员会"）是董事会按照股东 大会决议设立的专门工作机构，主要负责对公司长期发展战略和重大投资决策进 行研究并提出建议。 第二章 人员组成 第三条 战略委员会由三名董事组成，其中应至少包括一名独立董事。战略 委员会委员均由董事会选举产生。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第五条 战略委员会设主任委员一名，由董事长担任。 第六条 战略委员会委员任期与董事任期一致，委员任期届满，连选可以连 任。期间如有委员不再担任公司董事职务，则自动失去委员资格，并由委员会根 据上述规定补足委员人数。 第七条 ...

本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 辽宁何氏眼科医院集团股份有限公司(以下称"公司")于 2023 年 8 月 10 日召 开了 2023 年第一次临时股东大会，选举产生了第三届监事会非职工代表监事成 员，与公司职工代表大会选举产生的职工代表监事组成第三届监事会。经全体监 事一致提议并同意豁免临时监事会通知时限，第三届监事会第一次会议通知于当 日以口头的方式发出。第三届监事会第一次会议于同日在公司会议室以现场表决 的方式召开。 经全体监事同意，共同推举公司监事李晓松先生担任本次会议主持人。本 次会议应出席监事 3 名，实际出席监事 3 名。董事会秘书列席了本次会议。 会议的召集、召开及表决程序符合《公司法》等有关法律、行政法规、部门规章、 规范性文件和《公司章程》等相关规定。本次会议经过与会监事的认真讨论，投 票表决，形成如下决议。 二、监事会会议审议情况 经与会监事充分讨论、审议，形成决议如下： 证券代码：301103 证券简称：何氏眼科 公告编号：2023-034 辽宁何氏眼科医院集团股份有限公司 第三届监事会第一次会议 ...

北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2023 年第一次临时股东大会的 法律意见书 二〇二三年八月 北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于辽宁何氏眼科医院集团股份有限公司 2023 年第一次临时股东大会的 法律意见书 致：辽宁何氏眼科医院集团股份有限公司 根据辽宁何氏眼科医院集团股份有限公司（以下简称"公司"）与北京市中伦 律师事务所（以下简称"本所"）签订的《常年法律服务协议》的约定及受本所指 派，本所律师对公司 2023 年第一次临时股东大会（以下简称"本次股东大会"） 的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《 ...

证券代码： 301103 证券简称：何氏眼科 辽宁何氏眼科医院集团股份有限公司 投资者关系活动记录表 编号：2023-001 | 投资者关系活动 | □特定对象调研 □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | □ 现场参观 | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 (周四) 下午 2023 5 18 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事长、总经理何伟 | | 员姓名 | 2、董事、财务总监、董事会秘书邓明 | | | 3、董事、副总经理赵国华 | | | 4、副总经理卢山 | | | 5、保荐代表人钟坚刚 | | | 6、独立董事李慧 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、 ...

Financial Performance - The company's operating revenue for 2022 was ¥955,313,555.17, a decrease of 0.74% year-on-year[3]. - The net profit attributable to shareholders for 2022 was ¥33,206,224.80, down 61.55% compared to the previous year[3]. - The significant decline in net profit was primarily due to increased costs from technology investments and hiring of high-level talent[3]. - The cash flow from operating activities for 2022 was ¥147,979,292.70, a decrease of 30.72% compared to ¥213,605,810.89 in 2021[23]. - The total assets at the end of 2022 were ¥2,605,409,436.46, an increase of 83.33% from ¥1,421,131,071.37 at the end of 2021[23]. - The net assets attributable to shareholders at the end of 2022 were ¥2,174,236,402.39, up 107.14% from ¥1,049,654,207.77 at the end of 2021[23]. - The basic earnings per share for 2022 were ¥0.2242, a decrease of 69.27% from ¥0.7296 in 2021[23]. - The weighted average return on equity for 2022 was 1.74%, down from 8.58% in 2021[23]. - The company reported a significant decline in quarterly net profit, with a loss of ¥32,528,379.94 in Q4 2022[25]. - The company received government subsidies amounting to ¥4,860,279.09 in 2022, compared to ¥10,761,945.39 in 2021[29]. Market Trends and Opportunities - The ophthalmology service market in China reached a scale of 159.5 billion yuan in 2021, growing approximately 13% compared to 2020, with expectations for continued growth in the next five years due to increasing patient populations and rising health awareness[42]. - The annual compound growth rate of the consumer medical service market in China is projected to be 22.9% from 2021 to 2025, reaching 2.393 trillion yuan by 2025[37]. - The prevalence of myopia among children and adolescents in China was reported at 52.7% in 2020, an increase of 2.5 percentage points from 2019, indicating a growing patient base[38]. - The penetration rate for ophthalmic disease treatment in China remains low, with the number of patients significantly higher than in the U.S., suggesting substantial future market growth potential[40]. - The private ophthalmology institutions' market share increased from 17% in 2016 to 21% in 2021, indicating a trend towards faster expansion and market growth[42]. - The market for cataract and refractive surgeries remains the largest segment within ophthalmology services, while myopia prevention, dry eye syndrome, and retinal diseases are gaining market attention[43]. Business Strategy and Operations - The company has expanded its business in key national economic regions, including Beijing-Tianjin-Hebei, Yangtze River Delta, Guangdong-Hong Kong-Macao Greater Bay Area, and Chengdu-Chongqing area[44]. - The company operates a three-tier eye health service model, with 3 tertiary, 35 secondary, and 64 primary eye health service institutions as of the end of the reporting period[49]. - The company is focusing on developing new vision care services to address national needs for myopia prevention and management, while expanding its market presence beyond Liaoning province[47]. - The company is investing in digital transformation, enhancing its information systems like HIS and PACS, and building a Customer Data Platform (CDP) to improve user management and digital service capabilities[47]. - The company has adopted a unified procurement model to ensure quality and stability in acquiring medical supplies, leveraging competitive bidding and supplier evaluations[51]. - The company emphasizes a "Bright City" strategy, integrating medical, educational, production, and research resources to provide comprehensive eye health solutions[54]. - The company has a strong competitive advantage in the Liaoning market and is actively expanding into new markets, supported by a complete integration of medical education and research resources[53]. Research and Development - The company has trained over 50,000 doctors and management personnel through its training system, leveraging both domestic and international resources[56]. - In 2022, the company completed 11 clinical trial projects and is currently conducting 13 ongoing research projects[61]. - The company has established a strategic partnership with Johnson & Johnson Vision to advance new ophthalmic technologies and products in China[59]. - The company is actively developing a digital therapy application, Beishiyou®, for visual function training, marking a significant innovation in ophthalmic treatment[63]. - The company is focusing on precision medicine, achieving breakthroughs in genetic testing for hereditary retinal diseases[57]. - The company is enhancing its digital health services by integrating "Internet + healthcare" models to provide personalized treatment options[64]. Governance and Management - The company established a comprehensive governance structure including a shareholders' meeting, board of directors, independent directors, supervisory board, and senior management[130]. - The board of directors consists of 14 members, including 1 chairman and 5 independent directors, and held 5 meetings during the reporting period with full attendance[132]. - The supervisory board is composed of 3 members and held 4 meetings during the reporting period, ensuring effective oversight[133]. - The company has implemented a robust internal control system to enhance governance and risk management, continuously improving its operational effectiveness[134]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with shareholders through designated media[135]. - The company emphasizes investor relations management, maintaining communication through its official website and investor hotline[136]. Future Outlook - The company has set a revenue guidance of 1.5 billion RMB for the fiscal year 2023, projecting a growth rate of 25%[162]. - New product launches in the ophthalmology sector are expected to contribute an additional 200 million RMB in revenue in 2023[162]. - The company is expanding its market presence by opening 10 new clinics across major cities in China by the end of 2023[162]. - The management team emphasized a commitment to sustainable practices, aiming for a 40% reduction in operational waste by 2025[162]. - The company is exploring potential mergers and acquisitions to enhance its service offerings and market share[162]. - A strategic partnership with a leading medical technology firm is expected to enhance operational efficiency and patient care[162].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 306,811,212.93, representing a 26.91% increase compared to CNY 241,753,611.42 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was CNY 56,826,297.00, a significant increase of 117.82% from CNY 26,088,609.26 in the previous year[4] - Basic and diluted earnings per share for Q1 2023 were CNY 0.3596, up 63.16% from CNY 0.2204 in the previous year[4] - Total operating revenue for Q1 2023 reached CNY 306,811,212.93, an increase of 27% compared to CNY 241,753,611.42 in the same period last year[41] - The net profit for Q1 2023 was CNY 56,230,385.30, a significant increase of 115.5% compared to CNY 26,088,609.26 in Q1 2022[42] - Operating profit reached CNY 77,054,137.71, up from CNY 39,498,037.29, reflecting a growth of 95.1% year-over-year[42] - Total revenue from operating activities was CNY 325,923,079.64, compared to CNY 266,992,813.72 in the previous year, marking a growth of 22%[46] - Total comprehensive income for the period was CNY 56,230,732.85, compared to CNY 26,088,609.26 in the previous year, showing a growth of 115.5%[43] Cash Flow and Investments - The net cash flow from operating activities reached CNY 89,360,198.07, marking a 40.32% increase from CNY 63,683,424.40 in the same period last year[4] - The net cash flow from investing activities for the current period is -35.73 million yuan, a decrease of 168.25% year-on-year, mainly due to increased cash payments for investments and fixed asset acquisitions[28] - The company's cash and cash equivalents at the end of the period were CNY 1,679,507,989.65, down from CNY 1,925,186,152.38 at the end of the previous year[47] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 2,717,496,458.21, reflecting a 3.11% increase from CNY 2,605,409,436.46 at the end of the previous year[5] - Total liabilities increased to CNY 485,292,632.00 from CNY 459,676,501.22, marking an increase of about 5.5%[38] - The company's total equity as of March 31, 2023, was CNY 2,232,203,826.21, up from CNY 2,175,973,093.36 at the beginning of the year, indicating a growth of approximately 2.6%[39] Expenses - The operating cost for the current period is 162.04 million yuan, an increase of 12.27% year-on-year, attributed to the corresponding increase in costs due to the expansion of the business scale[24] - The income tax expense for the current period is 20.64 million yuan, an increase of 55.08% year-on-year, mainly due to the increase in taxable income resulting from revenue growth[27] - The company's management expenses for the current period are 40.57 million yuan, an increase of 40.03% year-on-year, primarily due to increases in labor costs, software service fees, consulting fees, and rental fees[24] - Sales expenses increased to CNY 33,760,100.39 from CNY 30,579,191.68, reflecting a rise of 7.1%[42] Accounts and Receivables - Accounts receivable increased by 61.61% compared to the end of the previous year, primarily due to an increase in receivables from medical insurance[14] - Accounts receivable increased to CNY 50,874,099.62 from CNY 31,480,161.65, representing a growth of approximately 62%[36] - Contract liabilities surged by 95.71% compared to the end of the previous year, attributed to an increase in advance payments received[19] - Contract liabilities rose to CNY 25,512,937.54 from CNY 13,035,929.20, representing an increase of about 96%[38] Strategic Initiatives - The company plans to continue expanding its market presence and investing in new technologies to enhance service delivery and operational efficiency[34] - The company has implemented a new accounting policy effective January 1, 2023, which has resulted in adjustments to deferred tax assets and liabilities[6] Other Financial Metrics - The company's financial expenses for the current period are -6.69 million yuan, a decrease of 197.24% year-on-year, mainly due to an increase in bank deposit interest[25] - The company's investment income for the current period is 1.28 million yuan, a growth of 100.00% compared to the same period last year, primarily due to increased returns from financial products[26] - Research and development expenses were CNY 165,166.61, indicating a focus on innovation despite overall expense increases[42] - The total number of ordinary shareholders at the end of the reporting period is 10,401[30]